# Laboratoires Cyclopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/laboratoires-cyclopharma

- Industry: Medical Devices & Equipment
- Headquarters: France
- Website: www.cyclopharma.fr
- Total disclosed funding: $5.5M
- Latest round: Series B (Jun 22, 2007)
- Investors on record: 4

## About

Laboratoires Cyclopharma SA is a French company specializing in the development and commercialization of innovative radiopharmaceuticals for medical imaging and therapy, focusing on enhancing diagnostic accuracy in oncology.Founded in 2000, Laboratoires Cyclopharma SA operates in France and focuses on developing radiopharmaceuticals for medical applications. The company was acquired by Denos from previous investors including Sofimac Partners and Tikehau Capital. The company has successfully raised EUR 4.615 mn in its latest funding round led by IXO Private Equity, bringing the total amount raised to EUR 4.615 mn with a current valuation of EUR 28.342 mn.Laboratoires Cyclopharma specializes in the development and commercialization of innovative radiopharmaceuticals primarily designed for medical imaging and therapy. Its core offerings include diagnostic and therapeutic agents that enhance imaging accuracy, particularly for oncology. The company's products are marketed to hospitals and imaging centers across Europe and Asia, addressing the growing demand for advanced imaging solutions.In 2023, Laboratoires Cyclopharma reported a revenue of EUR 91.69 mn and an EBITDA of EUR 18.76 mn. Revenue is generated through direct sales of its radiopharmaceutical products to healthcare institutions, supporting B2B relationships with hospitals and imaging centers.Laboratoires Cyclopharma plans to leverage recent funding to expand its product offerings and enter new markets. Future initiatives include launching new radiopharmaceutical products aimed at enhancing diagnostic capabilities by the end of 2024. The company is also targeting expansion into emerging healthcare markets in Asia and the Middle East within the next three years.

## Funding rounds

- Series B, Jun 22, 2007, $5.5M — Omnes Capital, Sofimac Partners, Tikehau Capital, Societe Generale Capital Partenaires

## Investors

- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series B
- Sofimac Partners (https://capitalatlas.ai/funds/sofimac-partners) — Series B
- Tikehau Capital — Series B
- Societe Generale Capital Partenaires (https://capitalatlas.ai/funds/societe-generale-capital-partenaires) — Series B